Dusica J Popovic1 
,
Mihalj Posa2,
Kosta J Popovic2,
Jovanka Kolarovic3,
Jovan K Popovic4
Pavle Z Banovic1
For correspondence:- Dusica Popovic Email: jovan.popovic@mf.uns.ac.rs
Accepted: 15 September 2017 Published: 31 October 2017
Citation: Popovic DJ, Posa M, Popovic KJ, Kolarovic J, Popovic JK.Banovic PZ. Application of a widely-used tropical anti-worm agent, mebendazole, in modern oncology. Trop J Pharm Res 2017; 16(10):2555-2562 doi: 10.4314/tjpr.v16i10.32
© 2017 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Although clinical trials have not been completed, it has already been confirmed that mebendazole, a well-known anti-parasitic drug widely used in the tropical areas, inhibits cancer cell growth. Preclinical studies show that mebendazole notably impedes the growth of malignant and metastatic tumors such as osteosarcoma and soft tissue sarcoma, melanoma, carcinoma (lung, colorectal, breast, ovarian, hepatocellular and adrenocortical), acute myeloid leukaemia, glioblastoma multiforme and meduloblastoma. Mebendazole can induce the depolymerization of microtubules in neoplasms and newly formed vasculature, stopping tumor growth and neoangiogenesis, along with other proposed mechanisms of action
Archives
News Updates
Fulltext in PDF